Spots Global Cancer Trial Database for progressive disease
Every month we try and update this database with for progressive disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03586661 | Deleterious BRC... Deleterious BRC... Endometrial Ade... High Grade Ovar... Platinum-Resist... Primary Periton... Progressive Dis... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Copanlisib Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma | NCT02189343 | Multiple Myelom... | ACY-1215 in com... | 18 Years - | Celgene | |
| Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Relapsed or Refractory Multiple Myeloma (BMT-03) | NCT02043847 | Multiple Myelom... Multiple Myelom... | Total Marrow Ir... Melphalan Filgrastim (G-C... Autologous tran... Total Marrow Ir... Melphalan Filgrastim (G-C... Autologous tran... Total Marrow Ir... Melphalan Filgrastim (G-C... Autologous tran... | 18 Years - 75 Years | University of Illinois at Chicago | |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | NCT03546426 | Mesothelioma, M... PD-L1 Negative Advanced Cancer Progressive Dis... | Pembrolizumab Autologous dend... Interleukin-2 | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | NCT04005144 | ALK Gene Rearra... Lung Non-Small ... Progressive Dis... ROS1 Gene Rearr... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Binimetinib Brigatinib | 18 Years - | University of California, San Francisco | |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | NCT04017650 | BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | NCT04205838 | Diffuse Large B... High Grade B-Ce... Progressive Dis... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine Fludarabine Pho... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Autologous Redirected RNA Meso-CIR T Cells | NCT01355965 | Malignant Pleur... | Autologous T ce... | 18 Years - | University of Pennsylvania | |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | NCT04017650 | BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer | NCT04005144 | ALK Gene Rearra... Lung Non-Small ... Progressive Dis... ROS1 Gene Rearr... Stage IIIB Lung... Stage IIIC Lung... Stage IV Lung C... Stage IVA Lung ... Stage IVB Lung ... | Binimetinib Brigatinib | 18 Years - | University of California, San Francisco | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | NCT04205838 | Diffuse Large B... High Grade B-Ce... Progressive Dis... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine Fludarabine Pho... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma | NCT04205838 | Diffuse Large B... High Grade B-Ce... Progressive Dis... Recurrent Diffu... Recurrent High ... Recurrent Prima... Recurrent Trans... Refractory Diff... Refractory High... Refractory Prim... Refractory Tran... | Anakinra Axicabtagene Ci... Cyclophosphamid... Fludarabine Fludarabine Pho... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET | NCT04954820 | Neuroendocrine ... Intestinal Well... Progressive Dis... | Lutathera | 18 Years - | Institut du Cancer de Montpellier - Val d'Aurelle | |
| Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | NCT03422393 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib | 18 Years - | University of California, San Diego | |
| Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib | NCT03422393 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Ibrutinib | 18 Years - | University of California, San Diego | |
| Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer | NCT04017650 | BRAF NP_004324.... Metastatic Colo... Metastatic Micr... Metastatic Rect... Progressive Dis... Recurrent Color... Stage III Color... Stage IIIA Colo... Stage IIIB Colo... Stage IIIC Colo... Stage IV Colore... Stage IVA Color... Stage IVB Color... Stage IVC Color... Unresectable Co... Unresectable Re... | Cetuximab Encorafenib Nivolumab | 18 Years - | M.D. Anderson Cancer Center | |
| Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies | NCT03546426 | Mesothelioma, M... PD-L1 Negative Advanced Cancer Progressive Dis... | Pembrolizumab Autologous dend... Interleukin-2 | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma | NCT03990571 | Metastatic Aden... Progressive Dis... Recurrent Adeno... | Avelumab Axitinib | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
